Ginkgo Bioworks (DNA) Q1 2026 earnings summary

Executive summary

• Strategic focus for 2026 is on autonomous labs, consolidating R&D services onto a single platform and leveraging AI and robotics to transform laboratory work and drive efficiency in bioscience R&D.

• Completed the spin-off/divestiture of the biosecurity unit in April 2026, allowing sharper focus on core autonomous lab initiatives.

• Early adoption and partnerships, including with Pacific Northwest National Labs, OpenAI, and government entities, are validating the autonomous lab model.

• Revenue for Q1 2026 was $19.5 million, down from $38.2 million in Q1 2025, primarily due to lower non-cash revenue and reduced scope of services for a major agriculture customer.

• Net loss from continuing operations was $76.1 million, an improvement from $83.3 million in Q1 2025.

Financial highlights

• Q1 2026 revenue was $19.5 million, down 49% year-over-year from $38.2 million in Q1 2025.

• Net loss from continuing operations improved to $76.1 million from $83.3 million year-over-year.

• Adjusted EBITDA was negative $42.3 million, a slight improvement from negative $44.2 million in Q1 2025.

• Cash burn for Q1 2026 was $48 million, down 17% from $58 million in Q1 2025.

• Ended Q1 2026 with $373.5 million in cash, cash equivalents, and marketable securities, with no bank debt.

Outlook and guidance

• Reaffirmed full-year 2026 cash burn guidance of $125 million–$150 million, balancing cost efficiency with investment in autonomous labs.

• Management expects R&D and G&A expenses to remain consistent or decline in 2026, reflecting the impact of restructuring.

• Expenditures are anticipated to exceed revenue over the next 12 months as investments continue in R&D and tools offerings.

• Cash resources are expected to fund operations for at least the next 12 months.